Hypergrowth and profitability continued, with oncology expansion, margin mix, EMR rollout, and MRD coverage as key watchpoints. [13][43][97][113]
| Quarter | Q3 FY25 |
|---|---|
| Call date | 2025-12-15 |
| Length | 52 minutes |
| EPS | $0.10 |
| EPS consensus | $0.16 |
| Revenue | $83.5M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q4 FY25
All BLLN earnings ยท Back to BLLN overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.